FOXO4-DRI dosing (preclinical regimens)
> Updated:
Human schedule
Controlled data on this compound are limited. The regimens below were gathered from public sources online (studies and protocols) and are given as a reference, not a usage plan.
FOXO4-DRI is given subcutaneously in short courses (a senolytic pattern, a few consecutive days, with the cycle repeated a few times per year). The figures below are a generalized reference drawn from preclinical work (Baar et al., 2017) and open community protocols; no human clinical trials exist.
This is a concise reference to regimens described for adults; it is not an individual prescription.
FOXO4-DRI dosing in the preclinical study and in community protocols is built the same way, on a short cycle with a break rather than daily use: that is a deliberate senolytic design choice, not a supply constraint.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start (3 consecutive days) | 0.5–1 mg subcutaneously per day | Starting dose |
| Main cycle (3 consecutive days) | 2–2.5 mg subcutaneously per day | Increase if needed |
| Cycle ceiling; cycle repeated 2–3x per year | up to 5 mg subcutaneously per day | Maximum in this schedule |
Practical dosing and effect details
In the study by Baar and colleagues (Cell, 2017, volume 169), mice received FOXO4-DRI at 5 mg/kg every other day, three injections total, rather than daily and continuously. That intermittent pattern selectively triggered apoptosis in senescent cells rather than healthy ones, and in old mice it restored fur density, kidney function, and physical fitness.
That mouse dose (mg/kg, intravenous) does not carry over directly to the human schedule on this page: the 0.5-5 mg subcutaneous, short 3-day cycles shown above come from preclinical work and open community protocols, not from the Baar study's own dosing. What the two sources share is the underlying principle: a short cycle with a break rather than continuous administration. No human clinical trials of FOXO4-DRI exist.
This is reference information for planning a research protocol, not a medical recommendation and not instructions for self-administration.
This reference is research-use material. The information is not medical advice and is not intended for diagnosis, treatment or prevention of disease.